/

Società

MI

Società

MINORYX

Di cosa scriviamo

OncologiaSaluteSanità

22 comunicati stampa

Guarda tutti i comunicati

Press Release cover image

23/07/2025

Salute

Sanità

Leriglitazone Marketing Authorization Application submitted for treatment of cerebral adrenoleukodystrophy has been validated by European Medicines Agency

Fonte

1.00

0

Press Release cover image

17/07/2025

Salute

Sanità

Minoryx receives a EUR 26.9m grant within the framework of the European IPCEI Med4Cure project for the continued development of leriglitazone in lethal orphan CNS diseases

Fonte

1.00

0

Press Release cover image

11/12/2024

Salute

Sanità

Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy

Fonte

1.00

0

Press Release cover image

11/12/2024

Salute

Sanità

Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy

Fonte

1.00

0

Press Release cover image

11/06/2024

Salute

Sanità

Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy in compassionate-use study published in Brain

Fonte

1.00

0

Press Release cover image

31/05/2024

Salute

Sanità

Update on Regulatory Review of NEZGLYAL® (leriglitazone) in the EU

Fonte

1.00

0

Press Release cover image

29/02/2024

Salute

Sanità

Rare Disease Day 2024 - Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy – special film launched

Fonte

1.00

0

Press Release cover image

26/01/2024

Salute

Sanità

Update on Regulatory Review of leriglitazone in the EU

Fonte

1.00

0

Press Release cover image

16/11/2023

Salute

Sanità

Minoryx announces enrollment of first patients with cerebral Adrenoleukodystrophy (cALD) in US Phase 3 clinical trial, CALYX

Fonte

1.00

0

Press Release cover image

31/05/2023

Salute

Sanità

Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy

Fonte

1.00

0

Seguaci

0

Compatibilità

0